Skip to main content

CG Oncology

CG Oncology Inc is an American clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for bladder cancer. The company develops cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy designed to selectively replicate inside cancer cells and induce an anti-tumor immune response. Main revenue drivers currently stem from strategic partnership collaborations, licensing agreements, and capital financing as clinical candidate development progresses. CG Oncology targets specialized oncology markets, medical researchers, and urological cancer patients in North America and global markets. The company holds a prominent position in precision oncology innovation for non-muscle invasive bladder cancer treatments. Headquartered in Irvine, California, CG Oncology Inc is listed on the Nasdaq Stock Market.

7 of the funds FundTelligence covers report a position in CG Oncology.

Legal name
CG Oncology Inc
Sector
Health Care
Country
United States
Funds holding it
7

Funds holding CG Oncology

Loading...